Business Roundup | January 24, 2011 Issue - Vol. 89 Issue 4 | Chemical & Engineering News
Volume 89 Issue 4 | p. 19 | Concentrates
Issue Date: January 24, 2011

Business Roundup

Department: Business

DSM has formed an alliance with Cleveland-based start-up Proxy Biomedical to develop DSM’s high-performance polyethylene fiber as a durable surgical mesh. The two expect to develop the mesh for orthopedic repairs.

Air Liquide plans to invest more than $54 million to build air separation facilities in the Indian states of Gujarat and Maharashtra. Projects include a facility to supply nitrogen to the Sezal Glass plant in Jhagadia and one to produce nitrogen for the new Kemrock Industries carbon fiber plant in Vadodara.

Rhodia facilities in Saint-Fons and La Rochelle, France, will process rare-earth materials contained in powders left over from the recycling of fluorescent light bulbs. The facilities will use a Rhodia-developed process to recover the materials starting in early 2012.

OCI, a South Korean chemical maker, has acquired CornerStone Power Development, a Chicago-based developer of utility-scale solar power plants. OCI manufactures high-purity polysilicon for solar cells. In December 2010, it announced that it will invest $1.6 billion in a 20,000-metric-ton-per-year plant in South Korea.

Materia has received a $17 million investment from the Midwest investment group Bader/Bernstein and Alfred Bader, cofounder in 1951 of Aldrich Chemical. Materia was founded in 1998 to commercialize olefin metathesis catalyst technology.

LanzaTech, a New Zealand-based waste-to-ethanol start-up, has signed an agreement with IndianOil to collaborate on a process that turns refinery waste gas into fuel-grade ethanol. The firms say the partnership will help IndianOil comply with renewable fuel standards in India.

International Flavors & Fragrances plans to invest more than $100 million in Asia over the next three years. The firm says the money will go to build a flavor manufacturing facility in Guangzhou, China, and a flavor and fragrance plant in Singapore.

Allos Therapeutics will reduce staff by about 13%, eliminating approximately 23 jobs and saving about $4 million. Cuts will come primarily from R&D. The firm, which markets the cancer treatment Folotyn, says its sales staff will be unaffected by the reduction.

ShangPharma, one of China’s largest contract research organizations, has inaugurated a facility in Shanghai’s Fengxian district for active pharmaceutical ingredients and advanced intermediates. ShangPharma says the plant will allow it to make pharmaceutical chemicals for Phase II and III clinical trials.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment